Bharat Biotech’s Covaxin

New Delhi: The health ministry on Thursday refuted allegations that there were irregularities in approvals given to Bharat Biotech for the manufacture of covid-19 vaccine Covaxin. "We condemn targeted narrative against COVAXIN put forth…

Hyderabad: Bharat Biotech on Friday issued a statement urging healthcare workers to be “vigilant” and ensure only Covaxin is being administered to the age group of 15-18 years. “We have received several reports of other Covid-19 vaccines…

New Delhi: The exports of COVID-19 vaccine Covaxin has been started, said Bharat Biotech on Monday. “Long pending export orders have been executed during November, to be further expanded during the following months. With the number of…

Manama: After 95 countries approved India's indigenously developed COVID-19 vaccination--Covaxin, now Bahrain has also approved the emergency use of it. "Bahrain's National Health Regulatory Authority @NHRABahrain approves the emergency…

New Delhi: Hong Kong on Wednesday announced that it has recognised Bharat Biotech's Covaxin on its approved Covid-19 vaccine list. Earlier in the day, Vietnam also gave its approval to Covaxin for emergency use, the ninth to be endorsed…

New Delhi: The Australian government today recognised Bharat Biotech's Covaxin for the purpose of establishing a traveller's vaccination status. " Covaxin (manufactured by Bharat Biotech, India) and BBIBP-CorV (manufactured by Sinopharm,…

New Delhi: The World Health Organisation (WHO) has sought "additional clarifications" from Bharat Biotech for its COVID-19 vaccine Covaxin to conduct a final "risk-benefit assessment" for Emergency Use Listing of the vaccine. The…

New Delhi: In a bid to check the real-world effectiveness of Covaxin, Hyderabad based Bharat Biotech on Wednesday informed that the company will conduct a phase 4 trial of its vaccine. The phase-3 trial data of the Covid-19 vaccine,…

New Delhi: Amid an ongoing struggle to vaccinate all above 18, Bharat Biotech received the approval for phase II and phase III clinical trials of vaccines on children between the age of two and 18 years. In short, India’s drug regulator…

New Delhi: The Subject Expert Committee (SEC) on Wednesday gave its nod to Bharat Biotech for the phase 2 and 3 human clinical trials of its Covid-19 vaccine Covaxin on 2 to 18-year-olds, according to reports. The trial will take place…